BackEloxx Pharmaceuticals Overview

Eloxx Pharmaceuticals Other Liabilities

Track Eloxx Pharmaceuticals's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Eloxx Pharmaceuticals Other Liabilities History

Loading

Eloxx Pharmaceuticals vs. peers: Other Liabilities Comparison

Loading

Eloxx Pharmaceuticals Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eloxx Pharmaceuticals (ELOX) FAQ

Eloxx Pharmaceuticals's other liabilities stands at $0 as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Eloxx Pharmaceuticals's other liabilities is expanding or contracting. Sustained growth in other liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Eloxx Pharmaceuticals's other liabilities evolved across reporting periods, while the comparison chart places ELOX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other liabilities is commonly used to spot outliers. Eloxx Pharmaceuticals's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.